Table 1 Characteristics of included studies
From: The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis
First author | Agents | Journal | Phase | Year | Treatment setting | No. of patients | Median follow-up time (months) | FIGO stage | Hazard ratio (95 % CI) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control group | Anti-angiogenic group | Control group | Anti-angiogenic group | PFS | OS | |||||||
Pujade-Lauraine E [8] | Bevacizumab | JCO | III | 2014 | Recurrent | 182 | 179 | 13.9 | 13 | — | 0.48 (0.38–0.60) | 0.85 (0.66–1.08) |
Aghajanian C [9] | Bevacizumab | JCO | III | 2012 | Recurrent | 242 | 242 | 24 | 24 | — | 0.48 (0.39–0.61) | 1.03 (0.79–1.33) |
Perren TJ [10] | Bevacizumab | NEJM | III | 2011 | Primary | 764 | 764 | 19.4 | 19.4 | I-IV | 0.87 (0.77–0.99) | 0.85 (0.69–1.04) |
Burger RA [11] | Bevacizumab | NEJM | III | 2011 | Primary | 625 | 623 | 17.4 | 17.4 | III-IV | 0.64 (0.55–0.76) | 0.92 (0.73–1.15) |
Monk BJ [12] | Trebananib | Lancet Oncology | III | 2014 | Recurrent | 458 | 461 | 10.1 | 10.1 | — | 0.66 (0.57–0.77) | 0.86 (0.69–1.08) |
Karlan BY [13]a | Trebananib | JCO | II | 2012 | Recurrent | 55 | 53 | 14.9 | 15.4 | I-IV | 0.81 (0.51–1.30) | 0.60 (0.34–1.06) |
Karlan BY [13]b | Trebananib | JCO | II | 2012 | Recurrent | 55 | 53 | 14.9 | 15.2 | I-IV | 0.75 (0.49–1.21) | 0.77 (0.45–1.31) |
du Bois A [14] | Pazopanib | JCO | III | 2014 | Primary | 468 | 472 | 24 | 24 | II-IV | 0.77 (0.64–0.91) | 1.08 (0.87–1.33) |
Liu JF [15] | Cediranib | Lancet Oncology | II | 2014 | Recurrent | 46 | 44 | 16.6 | 16.6 | — | 0.42 (0.23–0.76) | — |
Ledermann JA [16] | Cediranib | 2013 ESMO meeting | III | 2013 | Recurrent | — | — | — | — | — | 0.57 (0.45–0.74) | 0.70 (0.51–0.99) |
Ledermann JA [17] | Nintedanib | JCO | II | 2011 | Recurrent | 40 | 43 | — | — | I-IV | 0.65 (0.41–1.02) | 0.84 (0.51–1.39) |
du Bois A [18] | Nintedanib | 2013 ESGO meeting | III | 2013 | Primary | 455 | 911 | — | — | IIB-IV | 0.84 (0.72–0.98) | — |
Gotlieb WH [19] | Aflibercept | Lancet Oncology | II | 2012 | Recurrent | 26 | 29 | — | — | — | — | 1.01 (0.56–1.86) |